HIV medication-based urolithiasis

Clinical Kidney Journal

Volumn 7, Issue 2, 2014, Pages 121-126

  Izzedine, Hassane ^a   Lescure, François Xavier ^b,c   Bonnet, Fabrice ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

antiretroviral; HIV; renal failure; urolithiasis

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CREATININE; DARUNAVIR; DELAVIRDINE; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; CRYSTALLIZATION; CRYSTALLURIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFRARED SPECTROPHOTOMETRY; INTERSTITIAL NEPHRITIS; KIDNEY COLIC; KIDNEY FUNCTION; LITHOTRIPSY; LIVER CIRRHOSIS; LONG TERM CARE; MILD RENAL IMPAIRMENT; NEPHROLITHIASIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; URETER STENT; URETEROSCOPY; URINARY EXCRETION; UROLITHIASIS;

EID: 84897390091     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu008     Document Type: Review

References (60)

1. Teichman JMH. Acute renal colic fromureteral calculus. N Engl J Med 2004; 350: 684-693
2. Trinchieri A. Epidemiological trends in urolithiasis: impact on our health care systems. Urol Res 2006; 34: 151-156
3. Alexander RT, Hemmelgarn BR, Wiebe N et al. Kidney stones and kidney function loss: a cohort study. BMJ 2012; 345: e5287
4. Lehr D. Clinical toxicity of sulfonamides. Ann N Y Acad Sci 1957; 69: 417-447
5. Rule AD, Bergstralh EJ, Melton LJ III et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 804-811
6. Jungers P, Joly D, Barbey F et al. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44: 799-805 (Pubitemid 39445911)
7. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585 (Pubitemid 40720806)
8. Berns JS, Cohen RM, Silverman M et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997; 30: 558-560 (Pubitemid 27422304)
9. Kopp JB, Miller KD, Mican JA et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-125
10. Gagnon RF, Tecimer SN, Watters AK et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36: 507-515
11. Kopp JB, Falloon J, Filie A et al. Indinavir-associated interstitial nephritis and urothelial inflammation: Clinical and cytologic findings. Clin Infect Dis 2002; 34: 1122-1128 (Pubitemid 34289686)
12. Crixivan [package insert]. West Point, PA: Merck Pharmaceuticals, 1996
13. Boubaker K, Sudre P, Bally F et al. Changes in renal function associated with indinavir. AIDS 1998; 12: F249-F254 (Pubitemid 28558592)
14. Sarcletti M, Petter A, Romani N et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54: 261-270
15. Jaradat M, Phillips C, Yum MN et al. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 2000; 35: E16
16. Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50: 194-196 (Pubitemid 28434750)
17. Cattelan AM, Trevenzoli M, Naso A et al. Severe hypertension and renal atrophy associated with indinavir. Clin Infect Dis 2000; 30: 619-621 (Pubitemid 30205327)
18. Cattelan AM, Trevenzoli M, Sasset L et al. Indinavir and systemic hypertension. AIDS 2001; 15: 805-807 (Pubitemid 32423233)
19. Singh G. Latrogenic nephrogenic diabetes insipidus. AIDS 2003; 17: 1418
20. Martinez F, Mommeja-Marin H, Estepa-Maurice L et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13: 750-753 (Pubitemid 28119064)
21. Salahuddin S, Kok DK, Buchholz NNP. Influence of body temperature on indinavir crystallization under loop of Henle conditions. J Antimicrobial Chemother 2007; 59: 114-117 (Pubitemid 46017911)
22. Nadler RB, Rubenstein JN, Eggener SE et al. The etiology of urolithiasis in HIV infected patients. Am Urolog Assoc 2003; 169: 475-477 (Pubitemid 36132965)
23. Herman JS, Ives NJ, Nelson M et al. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001; 48: 355-360 (Pubitemid 32898805)
24. Daudon M, Estepa L, Viard JP et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349: 1294-1295 (Pubitemid 27192476)
25. Polhemus ME, Aronson NE. Persistent nephrolithiasis after discontinuation of indinavir therapy. Clin Infect Dis 1998; 27: 1536-1537 (Pubitemid 29242439)
26. Hortin GL, King C, Miller KD et al. Detection of indinavir crystals in urine: dependence on method of analysis. Arch Pathol Lab Med 2000; 124: 246-250 (Pubitemid 30090610)
27. Bruce RG, Munch LC, Hoven AD et al. Urolithiasis associated with the protease inhibitor indinavir. Urology 1997; 50: 513-518 (Pubitemid 27433208)
28. Gentle DL, Stoller ML, Jarrett TW et al. Protease inhibitorinduced urolithiasis. Urology 1997; 50: 508-511
29. Grunke M, Valerius T, Manger B et al. Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir. Clin Infect Dis 1997; 25: 1270-1271. (Pubitemid 27513239)
30. Molina J-M, Andrade-Villanueva J, Echevarria J et al. Oncedaily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, formanagement of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-332
31. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71 (Pubitemid 351228129)
32. Chan-Tack KM, Truffa MM, Struble KA et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21: 1215-1218 (Pubitemid 46763296)
33. Anderson PL, Lichtenstein KA, Gerig NE et al. Atazanavircontaining renal calculi in an HIV-infected patient. AIDS 2007; 21: 1060-1062 (Pubitemid 46684345)
34. Rockwood N, Mandalia S, Bower M et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavirboosted darunavir. AIDS 2011; 25: 1671-1673
35. Hamada Y, Nishijima T, Watanabe K et al. High incidence of renal stones among HIV-infected patients on ritonavirboosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-1269
36. Couzigou C, Daudon M, Meynard JL et al. Urolithiasis in HIVpositive patients treated with atazanavir. Clin Infect Dis. 2007; 45: e105-e108 (Pubitemid 47580370)
37. de Lastours V, Ferrari Rafael De Silva E, Daudon M et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 2013; 68: 1850-1856
38. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44: e81-e84 (Pubitemid 39445931)
39. Izzedine H, M'rad MB, Bardier A et al. Atazanavir crystal nephropathy. AIDS 2007; 21: 2357-2358
40. Schmid S, Opravil M, Moddel M et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007; 450: 665-670 (Pubitemid 46986233)
41. Viglietti D, Verine J, De Castro N et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavirboosted atazanavir. Antivir Ther 2011; 16: 119-121
42. Breilh D, Guinguené S, de Lédinghen V et al. Pharmacokinetics of boosted PI and NNRTI in HCV/HIV-co-infected patients [abstract 946]. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007, p. 433. http://www. retroconference. org/2007/PDFs/946. pdf (12 September 2007, date last accessed)
43. Reyataz (atazanavir sulfate). Full Prescription Information [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2006
44. Fabbiani M, Bracciale L, Doino M et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. J Infect 2011; 62: 319-321
45. Ryom L, Mocroft A, Lundgren J. HIV therapies and the kidney: some good, some not so good? Curr HIV/AIDS Rep 2012; 9: 111-120
46. Engeler DS, John H, Rentsch KM et al. Nelfinavir urinary stones. J Urol 2002; 167: 1384-1385 (Pubitemid 34132100)
47. Feicke A, Rentsch KM, Oertle D et al. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther 2008; 13: 733-734
48. Doco-Lecompte T, Garrec A, Thomas L et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004; 18: 705-706 (Pubitemid 38393477)
49. Green ST, McKendrick MW, Schmid ML et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS 1998; 9: 555 (Pubitemid 28423490)
50. Kassahun K, McIntosh I, Cui D et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657-1663 (Pubitemid 47296061)
51. Vassallo M, Dunais B, Naqvi A et al. Raltegravir-induced nephrolithiasis: a case report. AIDS. 2012; 26: 1323-1324
52. Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products. European Public Assessment Report (EPAR) on stocrin/efavirenz. http://www. emea. eu. int/humandocs/Humans/EPAR/Stocrin/ StocrinM. htm (19 May 2007, date last accessed)
53. Wirth GJ, Teuscher J, Graf JD et al. Efavirenz-induced urolithiasis. Urol Res 2006; 34: 288-289 (Pubitemid 44127148)
54. Izzedine H, Valantin MA, Daudon M et al. Efavirenz urolithiasis. AIDS 2007; 21: 1992
55. Hesse A, Straub M. Rational evaluation of urinary stone disease. Urol Res 2006; 34: 126-130
56. Reyataz. Prescription Information. Princeton, NJ: Bristol-Myers Squibb, 2008
57. Daudon M, Traxer O, Conort P et al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006; 17: 2026-2033 (Pubitemid 44036187)
58. Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004; 64: 245-275 (Pubitemid 38283043)
59. Turk C, Knoll T, Petrik A et al. Guidelines on Urolithiasis. Arnhem, The Netherlands: European Association of Urology, 2010. www. uroweb. org/gls/pdf/Urolithiasis%202010. pdf (4 October 2010, date last accessed)
60. Crixivan. Prescription Information. Whitehouse Station, NJ: Merck & Co., 2008